News

Filter

Current filters:

Guanfacine

1 to 9 of 14 results

Morgan Stanley analysts review drug stocks, upgrading AstraZeneca

22-01-2010

Analysts at stockbroker Morgan Stanley have recently changed their recommendations on a number of pharmaceutical…

AstraZenecaAventis PharmaEuropeFinancialGuanfacineGuanfacine HydrochlorideIntunivLicensingNeurologicalPharmaceuticalRocheSanofi-AventisShire

Intuniv cuts symptoms in ADHD children

26-05-2009

UK-based specialty pharmaceutical company Shire has reported that its clinical study of Intuniv (guanfacine)…

AlphaGuanfacineGuanfacine HydrochlorideIntunivProlastinShire

Shire's Intuniv improves ADHD upto 24hrs post dose

19-05-2008

UK drugmaker Shire's Intuniv (guanfacine) extended-release tablets, a non-stimulant selective alpha-2A-receptor…

AlphaGuanfacineGuanfacine HydrochlorideIntunivProlastinShire

Stock Commentary - New York - week to Oct 1, 2007

08-10-2007

NEW YORK: equities moved gently higher for the first three days of the reporting week to October 1, with…

AcebutololBetapaceFlecainideGenzymeGuanfacineGuanfacine HydrochlorideIntunivMaravirocMerck KGaAPfizerSectralSelzentrySotalolTambocor

Shire's Intuniv gets "approvable" FDA letter

02-07-2007

UK drugmaker Shire has received an "approvable" letter from the US Food and Drug Administration for Intuniv…

AlphaGuanfacineGuanfacine HydrochlorideIntunivProlastinShire

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top